Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 years or older~* Must have a suspected or proven infection~* Must have two or more sepsis-associated organ dysfunctions~Exclusion Criteria:~* Documented multiple organ dysfunction greater than 24 hours prior to start of study drug~* Actual body weight less than 30 kg or more than 135 kg~* Platelet count less than 30,000/mm\^3~* Active internal bleeding or at increased risk of bleeding~* Not expected to survive 28 days given the patient's pre-existing uncorrectable medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard therapy (Type: EXPERIMENTAL): 24 microgram/kilogram/hour (mcg/kg/hr) for 24 hours, followed by 24 mcg/kg/hr for an additional 72 hours
- Alternative therapy:moderate protein C deficiency (Type: EXPERIMENTAL): 24 mcg/kg/hr for 24 hours, followed by 24 mcg/kg/hr for an additional 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
- Alternative therapy:severe protein C deficiency (Type: EXPERIMENTAL): 24 mcg/kg/hr for 24 hours, followed by 30 or 36 mcg/kg/hr for 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)

Based on this trial design, predict the completion outcome and termination type (if applicable).